BRCA2 and central nervous system cancer: A semi-quantitative analysis of ATM and BRCA2 staining revealed a trend towards a lower mean nuclear IRS for ATM in gliomas from ATM GV versus non-ATM GV carriers, and for BRCA2 in gliomas from BRCA2 GV versus non-BRCA2 GV carriers (Fig. 4a, b).